Contact Us
Drug Search Results
More Filters [+]

Amibegron

Alternative Names: amibegron, sr58611a
Latest Update: 2023-06-01
Latest Update Note: PubMed Publication

Product Description

Amibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Amibegron)

Mechanisms of Action: ADRB3 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Amibegron

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Generalized anxiety disorder|Depressive Disorder, Major|Depressive Disorder|Conduct Disorder

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
TMAD

N/A

Not yet recruiting

Diabetic Foot|Arthritis, Rheumatoid|Osteoarthritis

2017-06-01

GEMINI

P3

Terminated

Generalized anxiety disorder

2008-09-02

ALBERIO

P3

Completed

Depressive Disorder, Major

2008-02-22

2005-004006-81

P3

Completed

Depressive Disorder, Major

2008-02-01

Recent News Events

Date

Type

Title

06/01/2023

PubMed

 Involvement of beta3-adrenergic receptors in relaxation mediated by nitric oxide in chicken basilar artery.

01/01/2022

PubMed

 Rotator Cuff Tear Size Regulates Fibroadipogenic Progenitor Number and Gene Expression Profile in the Supraspinatus Independent of Patient Age.

09/15/2021

PubMed

 Activation of β3-adrenoceptor increases the number of readily releasable glutamatergic vesicle via activating Ca2+/calmodulin/MLCK/myosin II pathway in the prefrontal cortex of juvenile rats.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions